none of the drugs supporting psychotherapy in treatment of alcoholism is reimbursed, and new, in which naltrexone is reimbursed within the catalogue of guaranteed health services in the treatment of alcohol-dependent patients. The analysis presents the costs incurred by public payer and by patient associated only with drugs that support psychotherapy in the considered target population. The costs were not discounted. Consumption of resources was estimated on the basis of epidemiological data and recommended duration of pharmacotherapies. The effect of changes of key parameters and assumptions of primary analysis on the results obtained from the perspective of the public payer was examined in the one-way sensitivity analysis. RESULTS: If the reimbursement of naltrexone is introduced, the annual expenses from the budget of National Health Fund would increase by PLN 11.7 million in the first year, and PLN 11.8 million in the second year of reimbursement. On the other hand, from the patient perspective reimbursement of naltrexone will bring significant cost savings which will annually amount to PLN 28.8 million in the first and second year of the refund. CONCLUSIONS: Reimbursement of naltrexone in the treatment of alcohol-dependent patients in Poland will bring additional costs incurred by public payer (National Health Fund) and patient's significant cost savings.
PMH21 DIFFERENCES IN DAILY AVERAGE CONSUMPTION AND DAILY COSTS OF DESVENLAFAXINE, VENLAFAXINE XR, DULOXETINE, AND ESCITALOPRAM AMONG COMMERCIALLY INSURED PATIENTS
Whiteley J 1 , Makin C 2 , Klingman D 2 , Alvir J 1 , Harnett J 1 1 Pfizer, Inc., New York, NY, USA, 2 IMS Health, Falls Church, VA, USA BACKGROUND: Differences in daily utilization of antidepressant therapies may have clinical and economic implications, particularly pharmacy expenditures for health plans. OBJECTIVES: To examine antidepressant daily average consumption (DACON) and drug cost per day for patients with major depressive disorder (MDD) newly initiating serotonin-norepinephrine reuptake inhibitors (SNRIs) or escitalopram. METHODS: A retrospective cohort analysis was conducted in commercially insured patients from July 1, 2008 through June 30, 2009. Patients diagnosed with MDD (ICD-9: 296.2x, 296.3x, or 311) and newly treated with generic desvenlafaxine, venlafaxine XR, duloxetine, or escitalopram were included. For each index medication, DACON was computed for each pill strength by dividing total units dispensed by total days' supply while the patient persisted on index therapy, then averaging across pill strengths, weighted by days' supply. Persistence was defined as length of therapy without exceeding a 30-day gap in drug coverage, and drug cost per day was estimated based on standard wholesale acquisition cost.
RESULTS:
The study population included 1,097 desvenlafaxine, 1,924 venlafaxine XR, 3,216 duloxetine, and 4,730 escitalopram initiators. Average DACON during the study period was significantly lower (PϽ0.001) for desvenlafaxine (1.04) vs venlafaxine XR (1.43), duloxetine (1.28), or escitalopram (1.07). Average cost per DACON during the study period was significantly lower (PϽ0.001) for desvenlafaxine ($3.89) vs venlafaxine XR ($6.13) and duloxetine ($5.45), but higher than escitalopram ($3.21). Average persistence (days) was significantly greater for desvenlafaxine (140.6) vs venlafaxine XR (127.3; PϽ0.001), duloxetine (133.4; Pϭ0.007), and escitalopram (121.8; PϽ0.001). CONCLUSIONS: Patients with MDD treated with desvenlafaxine had significantly lower DACON and greater persistence on index antidepressant therapy than patients treated with venlafaxine XR, duloxetine, or escitalopram, and the lowest DACON cost among the SNRIs. Health care decision makers may wish to consider utilization patterns and their economic impact when determining health care policy and treatment decisions.
PMH22 CLINICAL AND ECONOMIC CONSEQUENCES OF LONG-TERM USE OF BENZODIAZEPINES IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
Berger A 1 , Edelsberg J 1 , Treglia M 2 , Alvir J 3 , Oster G 1 1 PAI, Brookline, MA, USA, 2 Pfizer, Inc., New London, CT, USA, 3 Pfizer, Inc., New York, NY, USA OBJECTIVES: To compare patterns of healthcare utilization and cost in the 6-month periods immediately before and after the initiation of benzodiazepine therapy among patients with generalized anxiety disorder (GAD) deemed longterm users of such therapy. METHODS: Using a large US health insurance database, we identified all persons with evidence of GAD (ICD-9-CM diagnosis code 300.02) between 1/1/2003 and 12/31/2007 who began treatment with a benzodiazepine anxiolytic. The date of the first benzodiazepine claim was designated the "index date", and we limited attention to patients with evidence of use of benzodiazepines for Ն90 days. Patients with Ͻ6 months of complete data preceding and following their index date were excluded from the study sample ("pre-index" and "postindex", respectively). We then compared healthcare utilization and costs between the 6-month pre-index and post-index periods. All healthcare utilization-and corresponding costs-was characterized as possibly attributable to long-term use of benzodiazepines (such as "accident-related" [e.g., fractures] or "other possibly related" [e.g., mental confusion/disorientation, cognitive impairment, dizziness]) or not, based on relevant ICD-9-CM diagnosis codes. RESULTS: We identified a total of 866 patients who initiated benzodiazepine therapy for GAD and who met all other entry criteria; 75% began monotherapy with benzodiazepines, and 25% received such therapy on an add-on basis. Mean total healthcare costs over the 6-month post-index period increased by $2334 relative to pre-index (from $4637 [SDϭ$9840] to $6971 [$17,002]; pϽ0.01); the corresponding increase for care possibly attributed to long-term use of benzodiazepines (i.e., accident-related, other possibly related) was $1099 ($1757 [$7656] vs. $2856 [$14,836]; pϭ0.04). CONCLUSIONS: Healthcare costs increase in patients with GAD who receive Ն90 days of benzodiazepine therapy; a substantial proportion of this increase is attributable to care associated with accidents and other known sequelae of long-term benzodiazepine use.
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COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH AND WITHOUT MEDICATION FOR OPIOID DEPENDENCY
Baser O, Wang L, Xie L STATinMED Research, Ann Arbor, MI, USA OBJECTIVES: To compare the differences in healthcare costs and utilizations between opioid-dependent patients who were treated with and without medication. METHODS: We conducted a retrospective database analysis using commercial enrollees from a large U.S. health plan database from 2005 to 2009. Continuously eligible patients with at least one claim of opioid dependence during the identification period and an opioid use disorder diagnosis during the baseline period were included. Propensity score matching was applied to compare the risk-adjusted outcomes between the Any Medication Group and the No Medication Group. Baseline differences in age, gender, region, comorbid scores, socio-economic status, baseline healthcare utilization and costs were controlled. RESULTS: Descriptive analysis showed that patients in the Any Medication Group (nϭ10,523) were sicker, had more distinct psychiatric diagnoses and medication, and were more likely to have an Elixhauser index score of more than 3 when compared to patients from the No Medication Group (nϭ8,630). After risk adjustments, 6,658 patients from each group were matched. Patients in the No Medication Group stayed significantly longer in detoxification facilities, and had a higher number of detoxification and/or rehabilitation admission which translated to a higher cost burden. Also, patients in the No Medication Group had more opioid-related and substance abuse psychosocial provider services and higher total healthcare costs during a 6-month postindex period compared to patients in the Any Medication Group. CONCLUSIONS: After controlling for confounders such as demographic factors, comorbid conditions and baseline healthcare utilization, we showed that medication treatment affects follow-up healthcare resource utilization and costs. Patients treated without medication incurred higher healthcare costs and utilizations than patients who were treated with medication.
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COMPARISON OF HEALTH CARE COSTS AND UTILIZATIONS BETWEEN PATIENTS WHO WERE TREATED WITH PHARMACOLOGICAL AND NON-PHARMACOLOGICAL SUBSTANCE MEDICATIONS FOR ALCOHOL DEPENDENCY
Baser O, Wang L, Xie L STATinMED Research, Ann Arbor, MI, USA OBJECTIVES: To compare the differences in healthcare costs and utilizations between alcohol-dependent patients treated with pharmacological substances and those treated with non-pharmacological substance medication. METHODS: We conducted a retrospective database analysis using commercial enrollees from a large U.S. health plan database from 2005 to 2009. Continuously eligible patients with at least one claim of alcohol dependence during the identification period and an alcohol use disorder diagnosis during the baseline period were included. Propensity score matching was applied to compare the risk-adjusted outcomes between the No-Pharmacological Substance Group and the Any Pharmacological Substance Group. Baseline differences in age, gender, region, comorbid scores, socio-economic status, and baseline healthcare utilization and costs were controlled. RESULTS: Descriptive analysis shows that patients in the Any Pharmacological Substance Group (nϭ15,502) were older, more likely to be female, had more distinct psychiatric diagnoses and medication, and were more likely to have an Elixhauser index score of more than 3 when compared to patients from the A189 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
